Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation

Pharmaceutics

Kwangmeyung Kim¹  Seong Ik Jeon¹  Man Kyu Shim¹  Hanhee Cho²  Cheol-Hee Ahn² 

[1] Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea;Department of Materials Science and Engineering, Seoul National University, Seoul 08826, Korea;

关键词: albumin;    drug delivery system;    cancer-targeted therapy;    prodrug;   

DOI  :  10.3390/pharmaceutics14040728

来源: DOAJ

【 摘 要 】

Albumin has shown remarkable promise as a natural drug carrier by improving pharmacokinetic (PK) profiles of anticancer drugs for tumor-targeted delivery. The exogenous or endogenous albumin enhances the circulatory half-lives of anticancer drugs and passively target the tumors by the enhanced permeability and retention (EPR) effect. Thus, the albumin-based drug delivery leads to a potent antitumor efficacy in various preclinical models, and several candidates have been evaluated clinically. The most successful example is Abraxane, an exogenous human serum albumin (HSA)-bound paclitaxel formulation approved by the FDA and used to treat locally advanced or metastatic tumors. However, additional clinical translation of exogenous albumin formulations has not been approved to date because of their unexpectedly low delivery efficiency, which can increase the risk of systemic toxicity. To overcome these limitations, several prodrugs binding endogenous albumin covalently have been investigated owing to distinct advantages for a safe and more effective drug delivery. In this review, we give account of the different albumin-based drug delivery systems, from laboratory investigations to clinical applications, and their potential challenges, and the outlook for clinical translation is discussed. In addition, recent advances and progress of albumin-binding drugs to move more closely to the clinical settings are outlined.

【 授权许可】

Unknown